DDrare: Database of Drug Development for Rare Diseases

Searched query = "Frontotemporal lobar degeneration", "Frontotemporal dementia", "Semantic dementia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (R)-[N-metil-11C1-PK11195(PK); 18F-AV-1451; 18F-AV-45; 18F-FDG; 18F-RO6958948; AL; AL001; AMIODARONE; Amantadine; Amiodarone; Amyvid; BIIB092; Behavioral: Cognitive and Behavioral experimental tasks; Behavioral: ECOCAPTURE; Behavioral: ICM_APATHY_TASKS; C-11 PiB; Carbonate; Chloride; Citalopram; Davunetide; Davunetide (AL-108, NAP); Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau; Diagnostic Test: Flutemetamol F18 Injection; Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau; Diagnostic Test: Neuropsychological assessment; Diagnostic Test: Supplementary Neuropsychological Assessment - Parkinson's Disease; Diagnostic Test: [18F]-RO6958948; Donepezil; EVP-0334; F 18 T807; F-18; F-18 FDG; FRM-0334; Ferulic acid; Florbetapir (18F); Florbetapir 18F; Florbetapir 18F Injection; Flortaucipir; Flortaucipir F18; Flutemetamol; Flutemetamol F18; Galantamine; Galantamine hydrobromide; Histone Deacetylase Inhibitor; Intranasal oxytocin; LMTM; LMTM/TRx0237; Leucine; Leuco-methylthioninium bis(hydromethanesulfonate); Lithium Carbonate; Lithium carbonate; MTC TRx0014-001 capsules; Memantine; Memantine hydrochloride; Metformin; Methylprednisolone; Methylthioninium; Methylthioninium chloride; N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate); N,N,N?,N?-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate); N,N,N’,N’-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate); Neurohormonal mechanisms; Novolin-R insulin; Other: 13C6 Leucine; Other: MRI; Oxytocin; PEA-LUT; PR006; Phenothiazine; Pittsburgh Compound B; Pittsburgh Compound B (C-11 PiB); Prednisone; Procedure: Brain PET scan; Saline Nasal Mist; Sirolimus; Syntocinon; T807; TRx0237; Tau (18-F-AV-1451); Tolcapone; Vizamyl; Vizamyl (flutemetamol(F-18)); [18F]PI-2620

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-001489-85-BE (EUCTR)	05/03/2015	24/10/2014	A study to investigate 2 doses of investigational drug on patients with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation	A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation	Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation MedDRA version: 18.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: FRM-0334 INN or Proposed INN: Histone Deacetylase Inhibitor Other descriptive name: EVP-0334	FORUM Pharmaceuticals Inc.	NULL	Not Recruiting	Female: yes Male: yes	30	Phase 2	France;United States;Belgium;Netherlands;Italy;United Kingdom
2	EUCTR2014-001489-85-IT (EUCTR)	22/12/2014	02/10/2014	A study to investigate 2 doses of investigational drug on patients with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation	A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation	Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation MedDRA version: 17.0;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: FRM-0334 INN or Proposed INN: Histone Deacetylase Inhibitor Other descriptive name: EVP-0334	FORUM Pharmaceuticals Inc.	NULL	Not Recruiting	Female: yes Male: yes	30	Phase 2	France;United States;Belgium;Netherlands;United Kingdom;Italy
3	EUCTR2014-001489-85-NL (EUCTR)	19/12/2014	23/09/2014	A study to investigate 2 doses of investigational drug on patients with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation	A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation	Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation MedDRA version: 18.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: FRM-0334 INN or Proposed INN: Histone Deacetylase Inhibitor Other descriptive name: EVP-0334	FORUM Pharmaceuticals Inc.	NULL	Not Recruiting	Female: yes Male: yes	30	Phase 2	France;United States;Belgium;Netherlands;Italy;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2014-001489-85-BE
(EUCTR)

05/03/2015

24/10/2014

A study to investigate 2 doses of investigational drug on patients with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation

Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation
MedDRA version: 18.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: FRM-0334
INN or Proposed INN: Histone Deacetylase Inhibitor
Other descriptive name: EVP-0334

FORUM Pharmaceuticals Inc.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

France;United States;Belgium;Netherlands;Italy;United Kingdom

EUCTR2014-001489-85-IT
(EUCTR)

22/12/2014

02/10/2014

A study to investigate 2 doses of investigational drug on patients with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation

Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation
MedDRA version: 17.0;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: FRM-0334
INN or Proposed INN: Histone Deacetylase Inhibitor
Other descriptive name: EVP-0334

FORUM Pharmaceuticals Inc.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

France;United States;Belgium;Netherlands;United Kingdom;Italy

EUCTR2014-001489-85-NL
(EUCTR)

19/12/2014

23/09/2014

A study to investigate 2 doses of investigational drug on patients with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation

Product Code: FRM-0334
INN or Proposed INN: Histone Deacetylase Inhibitor
Other descriptive name: EVP-0334

FORUM Pharmaceuticals Inc.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

France;United States;Belgium;Netherlands;Italy;United Kingdom